SUMMIT N.J.&8211;BUSINESS WIRE&8211;Celgene Corporation NASDAQ CELG today announced that the GED0301 mongersen phase III REVOLVE trial CD002 in Crohns disease CD and the extension trial SUSTAIN CD004 will discontinue. Celgene has decided to stop th...
↧